期刊文献+

足量泼尼松联合环磷酰胺治疗IgA肾病的疗效及影响因素 被引量:5

Efficacy and Influencing Factors of Adequate Prednisone Combined with Cyclophosphamide Therapy in the Treatment of IgA Nephropathy
下载PDF
导出
摘要 目的探讨足量泼尼松联合环磷酰胺治疗IgA肾病(IgAN)的疗效,并分析其影响因素。方法收集2018年1月—2020年1月在成都中医药大学附属医院经肾活检确诊为IgAN并使用足量泼尼松联合环磷酰胺治疗的33例患者临床资料,分析疗效及影响因素。结果33例患者经治疗后完全缓解10例(30.30%),部分缓解11例(33.33%),未缓解12例(32.36%),总缓解21例(63.64%)。缓解组年龄、24 h尿蛋白定量、Lee氏分级均低于未缓解组(P<0.05)。依据牛津分型分组后,比较各组缓解率:肾小球毛细血管内皮细胞增生(E)1组>E0组(P<0.05);肾小管萎缩和(或)肾间质纤维化(T)2组<T0组和T1组(P<0.05),T1组<T0组(P<0.05);新月体(C)2组<C0组和C1组(P<0.05),C1组和C0组缓解率差异无统计学意义。结论足量泼尼松联合环磷酰胺治疗IgAN疗效显著;年龄越大、24 h尿蛋白定量水平越高、肾小管萎缩和/或肾间质纤维化程度越严重、新月体越多,缓解率越低;E1、C1对足量泼尼松联合环磷酰胺治疗具有良好应答。 Objective To investigate the efficacy of adequate prednisone combined with cyclophosphamide in the treatment of IgAN,and analyze its influencing factors.Methods Review 33 patients who were diagnosed with IgAN by renal biopsy and were treated with sufficient prednisone combined with cyclophosphamide intravenous pulse therapy in the nephrology department of our hospital from January 2018 to January 2020 were collected,and the efficacy and factors affecting the efficacy were analyzed.Results After treatment,33 patients had complete remission in 10 cases(30.30%),partial remission in 11 cases(33.33%),no remission in 12 cases(32.36%),and total remission in 21 cases(63.64%).The age,24-hour urine protein quantification,and Lee's grade in the remission group were lower than in the non-remission group(P<0.05).After grouping according to Oxford classification,compare the remission rate of each group were compared:glomerular capillary endothelial cell hyperplasia(E)1 group>E0 group(P<0.05);renal tubular atrophy and/or renal interstitial fibrosis(T)2 groups<T0 group and T1 group(P<0.05),T1 group<T0 group(P<0.05);crescent(C)2 groups<C0 group and C1 group(P<0.05);there was no significant difference in remission rate between C1 group and C0 groups.Conclusion Adequate prednisone dose combined with cyclophosphamide therapy has a significant effect on IgAN;the older the age,the higher the 24-hour urine protein level,the more severe the renal tubular atrophy and/or the renal interstitial fibrosis,the more crescents,and the lower the remission rate;E1 and C1 have a good response to adequate doses of prednisone combined with cyclophosphamide intravenous pulse therapy.
作者 王梦平 孙健超 金畅 董建华 唐诗韵 WANG Mengping;SUN Jianchao;JIN Chang;DONG Jianhua;TANG Shiyun(No.1 Department of Nephrology,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China;No.2 Department of Cardiovascular Medicine,the Eighth People's Hospital of Chengdu,Chengdu 610083,China;Department of Nephrology,the People's Hospital of Leshan,Leshan 614099,China;GCP Center,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China)
出处 《医药导报》 CAS 北大核心 2023年第8期1172-1177,共6页 Herald of Medicine
基金 成都中医药大学附属医院科技发展基金课题(19PJ02) 成都中医药大学附属医院科技发展基金课题(21MZ11)。
关键词 泼尼松 环磷酰胺 IGA肾病 疗效 影响因素 Prednisone Cyclophosphamide IgA nephropathy Curative effect Influence factor
  • 相关文献

参考文献7

二级参考文献35

  • 1Kidney Disease : Improving Global Outcomes (KDIGO) Glomerulo- nephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis [ J 1. Kidney Int,2012, Suppl ( 2 ) : 139 - 274.
  • 2Reich HN,Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgAN [ J ]. J Am Soc lephrol,2007,18 ( 12 ) : 3177 -3183.
  • 3Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy : rationale, clinicopathological correlations, and clas- sification [ J 1- Kidney Int 2009,76 (5) :534 - 545.
  • 4Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgAN with ACE inhibitors: A randomized and controlled trial [ J ]. J Am Soc Nephro1,2003,14 ( 6 ) : 1578 - 1583.
  • 5Li PKT, Leung CB, Chow KM, ct al. Hong Kong study using Valsar- tan in IgAN (HKVIN)- A double-blind randomized placebo-con- trolled study[ J l. Am J Kidney Dis,2006,47 (5) :751 -760.
  • 6Coppo R, Peruzzi L, Amorc A, ctal. IgACE : a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in chil- dren and young people with IgAN and moderate protcinuria [ J ]. J Am Soc Nephrol,2007,18 (6) : 1880 - 1888.
  • 7Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgAN : long-term results of a randomized, controlled trial [ J ]. J Am Soc Nephro1,2004,15 ( 1 ) : 157 - 163.
  • 8Manno C ,Torres DD, Rossini M, et al. Randomized controlled clini- cal trial of corticosteroids plus ACE-inhibitors with long-term follow- up in proteinuric IgAN [ J 1. Nephrol Dial Transplant, 2009,24 (12) :3694 -3701.
  • 9Lv J, Zhang H, Chert Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgAN : a randomized controlled trial [ J 1. Am J Kidney Dis, 2009,53( 1 ) :26 -32.
  • 10Strippoli GF, Maione A, Schena FP, et al. IgAN :a disease in search of a large-scale clinical trial to reliably inform practice [ J 1. Am J Kidney Dis ,2009,53 ( 1 ) :5 - 8.

共引文献375

同被引文献78

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部